Abstract

Risk classification and tailoring of treatment are essential for improving outcome for patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Both patient and leukemia-specific characteristics assessed using morphology, cytogenetics, molecular biology, and multicolor flow cytometry are relevant at diagnosis and during induction, consolidation, and maintenance phases of the treatment. In particular, minimal residual disease (MRD) during therapy has potential as a prognostic factor of outcome, determination of response to therapy, and direction of targeted therapy. MRD can be determined by cell surface markers using multicolor flow cytometry, whereas leukemia-specific translocations and mutations are measured using polymerase chain reaction–based techniques and recently using next-generation sequencing. All these methods of MRD detection have their (dis)advantages, and all need to be standardized, prospectively validated, and improved to be used for uniform clinical decision making and a potential surrogate end point for clinical trials testing novel treatment strategies. Important issues to be solved are time point of MRD measurement and threshold for MRD positivity. MRD is used for stem cell transplantation (SCT) selection in the large subgroup of patients with an intermediate risk profile. Patients who are MRD positive will benefit from allo-SCT. However, MRD-negative patients have a better chance of survival after SCT. Therefore, it is debated whether MRD-positive patients should be extensively treated to become MRD negative before SCT. Either way, accurate monitoring of potential residual or upcoming disease is mandatory. Tailoring therapy according to MRD monitoring may be the most successful way to provide appropriate specifically targeted, personalized treatment.

References

References
1.
Ossenkoppele
G
,
Schuurhuis
GJ
.
MRD in AML: time for redefinition of CR?
Blood
.
2013
;
121
(
12
):
2166
-
2168
.
2.
Curran
E
,
Stock
W
.
Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
.
Blood
.
2019
;
133
(
16
):
1715
-
1719
.
3.
Berry
DA
,
Zhou
S
,
Higley
H
, et al
.
Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis
.
JAMA Oncol
.
2017
;
3
(
7
):
e170580
.
4.
Owen
C
,
Christofides
A
,
Johnson
N
,
Lawrence
T
,
MacDonald
D
,
Ward
C
.
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia
.
Leuk Lymphoma
.
2017
;
58
(
12
):
2777
-
2785
.
5.
Yanamandra
U
,
Kumar
SK
.
Minimal residual disease analysis in myeloma - when, why and where
.
Leuk Lymphoma
.
2018
;
59
(
8
):
1772
-
1784
.
6.
Bassan
R
,
Hoelzer
D
.
Modern therapy of acute lymphoblastic leukemia
.
J Clin Oncol
.
2011
;
29
(
5
):
532
-
543
.
7.
Döhner
H
,
Estey
E
,
Grimwade
D
, et al
.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
.
Blood
.
2017
;
129
(
4
):
424
-
447
.
8.
Bain
BJ
,
Béné
MC
.
Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia
.
Acta Haematol
.
2019
;
141
(
4
):
232
-
244
.
9.
Schoch
C
,
Schnittger
S
,
Kern
W
, et al
.
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia
.
Hematol J
.
2002
;
3
(
5
):
259
-
263
.
10.
Falini
B
,
Mecucci
C
,
Tiacci
E
, et al
;
GIMEMA Acute Leukemia Working Party
.
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
.
N Engl J Med
.
2005
;
352
(
3
):
254
-
266
.
11.
Paietta
E
,
Andersen
J
,
Gallagher
R
, et al
.
The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study
.
Leukemia
.
1994
;
8
(
7
):
1108
-
1112
.
12.
Cai
SF
,
Levine
RL
.
Genetic and epigenetic determinants of AML pathogenesis
.
Semin Hematol
.
2019
;
56
(
2
):
84
-
89
.
13.
Ossenkoppele
GJ
,
Schuurhuis
GJ
.
MRD in AML: it is time to change the definition of remission
.
Best Pract Res Clin Haematol
.
2014
;
27
(
3-4
):
265
-
271
.
14.
Freeman
SD
,
Hills
RK
,
Russell
NH
, et al
;
HOVON AML Trial Group
.
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults
.
Br J Haematol
.
2019
;
186
(
1
):
130
-
133
.
15.
Jourdan
E
,
Boissel
N
,
Chevret
S
, et al
;
French AML Intergroup
.
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
.
Blood
.
2013
;
121
(
12
):
2213
-
2223
.
16.
Balsat
M
,
Renneville
A
,
Thomas
X
, et al
.
Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute Leukemia French Association Group
.
J Clin Oncol
.
2017
;
35
(
2
):
185
-
193
.
17.
Krönke
J
,
Schlenk
RF
,
Jensen
K-O
, et al
.
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group
.
J Clin Oncol
.
2011
;
29
(
19
):
2709
-
2716
.
18.
Gorello
P
,
Cazzaniga
G
,
Alberti
F
, et al
.
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
.
Leukemia
.
2006
;
20
(
6
):
1103
-
1108
.
19.
Yin
JAL
,
O’Brien
MA
,
Hills
RK
,
Daly
SB
,
Wheatley
K
,
Burnett
AK
.
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
.
Blood
.
2012
;
120
(
14
):
2826
-
2835
.
20.
Ivey
A
,
Hills
RK
,
Simpson
MA
, et al
;
UK National Cancer Research Institute AML Working Group
.
Assessment of minimal residual disease in standard-risk AML
.
N Engl J Med
.
2016
;
374
(
5
):
422
-
433
.
21.
Thol
F
,
Gabdoulline
R
,
Liebich
A
, et al
.
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
.
Blood
.
2018
;
132
(
16
):
1703
-
1713
.
22.
Morita
K
,
Kantarjian
HM
,
Wang
F
, et al
.
Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia
.
J Clin Oncol
.
2018
;
36
(
18
):
1788
-
1797
.
23.
Jongen-Lavrencic
M
,
Grob
T
,
Hanekamp
D
, et al
.
Molecular minimal residual disease in acute myeloid leukemia
.
N Engl J Med
.
2018
;
378
(
13
):
1189
-
1199
.
24.
Cloos
J
,
Harris
JR
,
Janssen
JJWM
, et al
.
Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia
.
J. Vis. Exp.
2018
;(
133
):
25.
Quek
L
,
Ferguson
P
,
Metzner
M
, et al
.
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
.
Blood Adv
.
2016
;
1
(
3
):
193
-
204
.
26.
Christopher
M
,
DiPersio
JF
,
Ley
TJ
.
Immune escape of AML cells after transplantation. Reply
.
N Engl J Med
.
2019
;
380
(
13
):
1290
.
27.
Schuurhuis
GJ
,
Heuser
M
,
Freeman
S
, et al
.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
.
Blood
.
2018
;
131
(
12
):
1275
-
1291
.
28.
Lacombe
F
,
Campos
L
,
Allou
K
, et al
;
Groupe d’Etude Immunologique des Leucémies (GEIL)
.
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia
.
Hematol Oncol
.
2018
;
36
(
2
):
422
-
428
.
29.
Lacombe
F
,
Dupont
B
,
Lechevalier
N
,
Vial
JP
,
Béné
MC
.
Innovation in flow cytometry analysis: a new paradigm delineating normal or diseased bone marrow sets through machine learning.
HemaSphere
.
2019
;
3
(
2
):
e173
.
30.
Grimwade
D
,
Ivey
A
,
Huntly
BJP
.
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
.
Blood
.
2016
;
127
(
1
):
29
-
41
.
31.
Appelbaum
FR
.
Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy
.
Best Pract Res Clin Haematol
.
2018
;
31
(
4
):
405
-
409
.
32.
Grimwade
D
,
Jovanovic
JV
,
Hills
RK
, et al
.
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
.
J Clin Oncol
.
2009
;
27
(
22
):
3650
-
3658
.
33.
Ehinger
M
,
Pettersson
L
.
Measurable residual disease testing for personalized treatment of acute myeloid leukemia
.
APMIS
.
2019
;
127
(
5
):
337
-
351
.
34.
Ommen
HB
.
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies
.
Ther Adv Hematol
.
2016
;
7
(
1
):
3
-
16
.
35.
Bachas
C
,
Schuurhuis
GJ
,
Hollink
IH
, et al
.
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
.
Blood
.
2010
;
116
(
15
):
2752
-
2758
.
36.
Rautenberg
C
,
Pechtel
S
,
Hildebrandt
B
, et al
.
Wilms’ tumor 1 gene expression using a standardized european leukemianet-certified assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation
.
Biol Blood Marrow Transplant
.
2018
;
24
(
11
):
2337
-
2343
.
37.
Levine
RL
,
Valk
PJM
.
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
.
Haematologica
.
2019
;
104
(
5
):
868
-
871
.
38.
Bohl
SR
,
Bullinger
L
,
Rücker
FG
.
New targeted agents in acute myeloid leukemia: new hope on the rise
.
Int J Mol Sci
.
2019
;
20
(
8
):
1983
.
39.
Guénot
C
,
Lacombe
F
,
Allou
K
, et al
.
Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia
.
Leukemia.
2019
;
33
(
7
):
1814
-
1816
.
40.
Zeijlemaker
W
,
Kelder
A
,
Oussoren-Brockhoff
YJM
, et al
.
Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia
.
Leukemia
.
2016
;
30
(
3
):
708
-
715
.
41.
Buccisano
F
,
Maurillo
L
,
Schuurhuis
GJ
, et al
.
The emerging role of measurable residual disease detection in AML in morphologic remission
.
Semin Hematol
.
2019
;
56
(
2
):
125
-
130
.
42.
Walter
RB
,
Gooley
TA
,
Wood
BL
, et al
.
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia
.
J Clin Oncol
.
2011
;
29
(
9
):
1190
-
1197
.
43.
Walter
RB
,
Buckley
SA
,
Pagel
JM
, et al
.
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
.
Blood
.
2013
;
122
(
10
):
1813
-
1821
.
44.
Othus
M
,
Wood
BL
,
Stirewalt
DL
, et al
.
Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
.
Leukemia
.
2016
;
30
(
10
):
2080
-
2083
.
45.
Buckley
SA
,
Wood
BL
,
Othus
M
, et al
.
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
.
Haematologica
.
2017
;
102
(
5
):
865
-
873
.
46.
Walter
RB
,
Gyurkocza
B
,
Storer
BE
, et al
.
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
.
Leukemia
.
2015
;
29
(
1
):
137
-
144
.
47.
Ustun
C
,
Courville
EL
,
DeFor
T
, et al
.
Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia
.
Biol Blood Marrow Transplant
.
2016
;
22
(
4
):
669
-
675
.
48.
Milano
F
,
Gooley
T
,
Wood
B
, et al
.
Cord-blood transplantation in patients with minimal residual disease
.
N Engl J Med
.
2016
;
375
(
10
):
944
-
953
.
49.
Hourigan
CS
,
Haferlach
T
,
Hokland
P
.
Cord-blood transplantation in patients with minimal residual disease
.
N Engl J Med
.
2016
;
375
(
22
):
2204
.
50.
Platzbecker
U
,
Middeke
JM
,
Sockel
K
, et al
.
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
.
Lancet Oncol
.
2018
;
19
(
12
):
1668
-
1679
.
51.
Pozzi
S
,
Geroldi
S
,
Tedone
E
, et al
.
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression
.
Br J Haematol
.
2013
;
160
(
4
):
503
-
509
.
52.
Yan
C-H
,
Liu
QF
,
Wu
DP
, et al
.
Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia
.
Biol Blood Marrow Transplant
.
2017
;
23
(
8
):
1311
-
1319
.
53.
Claiborne
J
,
Bandyopathyay
D
,
Roberts
C
, et al
.
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy
.
Leuk Lymphoma
.
2019
;
1
-
11
.
54.
Schmid
C
,
Labopin
M
,
Nagler
A
, et al
;
EBMT Acute Leukemia Working Party
.
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party
.
J Clin Oncol
.
2007
;
25
(
31
):
4938
-
4945
.
55.
Pochon
C
,
Oger
E
,
Michel
G
, et al
.
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react
.
Br J Haematol
.
2015
;
169
(
2
):
249
-
261
.
56.
Kim
Y-J
,
Kim
D-W
,
Lee
S
, et al
.
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial
.
Bone Marrow Transplant
.
2004
;
33
(
5
):
535
-
542
.
57.
Lee
CJ
,
Savani
BN
,
Mohty
M
, et al
.
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
.
Bone Marrow Transplant
.
2019
;
54
(
4
):
519
-
530
.
58.
Dillon
R
,
Hills
R
,
Freeman
S
, et al
.
Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study
.
EHA Library
.
2019
;
267366
:
S1612
.
59.
Ossenkoppele
G
,
Schuurhuis
GJ
,
van de Loosdrecht
A
,
Cloos
J
.
Can we incorporate MRD assessment into clinical practice in AML?
Best Pract Res Clin Haematol
.
2019
;
32
(
2
):
186
-
191
.
60.
Terwijn
M
,
Zeijlemaker
W
,
Kelder
A
, et al
.
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia
.
PLoS One
.
2014
;
9
(
9
):
e107587
.
61.
Zeijlemaker
W
,
Grob
T
,
Meijer
R
, et al
.
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
.
Leukemia
.
2019
;
33
(
5
):
1102
-
1112
.
62.
Zeijlemaker
W
,
Kelder
A
,
Oussoren-Brockhoff
YJM
, et al
.
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
.
Leukemia
.
2016
;
30
(
2
):
439
-
446
.
63.
Gomez-Arteaga
A
,
Guzman
ML
.
Minimal residual disease in acute myeloid leukemia
.
Adv Exp Med Biol
.
2018
;
1100
:
111
-
125
.
64.
Brüggemann
M
,
Kotrova
M
.
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
.
Blood Adv
.
2017
;
1
(
25
):
2456
-
2466
.
65.
Cilloni
D
,
Petiti
J
,
Rosso
V
, et al
.
Digital PCR in myeloid malignancies: ready to replace quantitative PCR?
Int J Mol Sci
.
2019
;
20
(
9
):
2249
.
66.
Monter
A
,
Nomdedéu
JF
.
ClonoSEQ assay for the detection of lymphoid malignancies
.
Expert Rev Mol Diagn
.
2019
;
19
(
7
):
571
-
578
.
67.
Ragon
BK
,
Daver
N
,
Garcia-Manero
G
, et al
.
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
.
Am J Hematol
.
2017
;
92
(
9
):
845
-
850
.
68.
Rothenberg-Thurley
M
,
Amler
S
,
Goerlich
D
, et al
.
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
.
Leukemia
.
2018
;
32
(
7
):
1598
-
1608
.
69.
Guolo
F
,
Minetto
P
,
Clavio
M
, et al
.
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia
.
Haematologica
.
2017
;
102
(
9
):
e348
-
e351
.
70.
Cilloni
D
,
Renneville
A
,
Hermitte
F
, et al
.
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study
.
J Clin Oncol
.
2009
;
27
(
31
):
5195
-
5201
.
71.
Modvig
S
,
Madsen
HO
,
Siitonen
SM
, et al
.
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia
.
Leukemia
.
2019
;
33
(
6
):
1324
-
1336
.
72.
Tomuleasa
C
,
Selicean
C
,
Cismas
S
, et al
.
Minimal residual disease in chronic lymphocytic leukemia: a consensus paper that presents the clinical impact of the presently available laboratory approaches
.
Crit Rev Clin Lab Sci
.
2018
;
55
(
5
):
329
-
345
.
73.
Terwijn
M
,
van Putten
WLJ
,
Kelder
A
, et al
.
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study
.
J Clin Oncol
.
2013
;
31
(
31
):
3889
-
3897
.
74.
Wang
Z
,
Guo
M
,
Zhang
Y
, et al
.
The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different‐from‐normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation [published online ahead of print 4 June 2019]
.
Int J Lab Hematol
.
doi:10.1111/ijlh.13070
.
75.
Buccisano
F
,
Maurillo
L
,
Piciocchi
A
, et al
.
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia
.
Bone Marrow Transplant
.
2017
;
52
(
3
):
473
-
475
.
76.
Kim
T
,
Moon
JH
,
Ahn
J-S
, et al
.
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse
.
Blood
.
2018
;
132
(
15
):
1604
-
1613
.
77.
Zhou
Y
,
Othus
M
,
Araki
D
, et al
.
Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
.
Leukemia
.
2016
;
30
(
7
):
1456
-
1464
.
You do not currently have access to this content.

Comments

0 Comments